Agenus Inc news

   Watch this stock
Showing stories 1 - 10 of about 82   

Articles published

AGEN 2.83 +0.11 (4.04%)
price chart
Agenus Inc. (NASDAQ:AGEN): Favorite Pick
Zacks Research, a reputed firm in the market, planned a poll of sell-side analysts. Going by this poll, Agenus Inc. (NASDAQ:AGEN) was given rating of 1.4.
Agenus Inc. (NASDAQ:AGEN) PT & Analyst Recommendation Review  Uptick Analyst
How Many Agenus Inc (NASDAQ:AGEN)'s Analysts Are Bearish?  Sonoran Weekly Review
Company Update (NASDAQ:AGEN): Agenus Inc Announces Clearance of ...
Agenus Inc (NASDAQ:AGEN), an immuno-oncology company developing checkpoint modulator antibodies and cancer vaccines, announced today that the U.S.
Form 8-K AGENUS INC For: Jan 21
Agenus Receives FDA Clearance for INDs of Anti-CTLA-4 and Anti-GITR ...
Analyst Coverage Updates - Agenus Inc. (AGEN)
Recently stock market analysts have updated their consensus ratings on shares of Agenus Inc. (AGEN). The latest broker reports which are currently outstanding on Thursday 11th of February state 3 analysts have a rating of “strong buy”, 2 analysts “buy ...
Company Update (NASDAQ:AGEN): Agenus Inc Completes XOMA Antibody Manufacturing ...
Agenus Inc (NASDAQ:AGEN), an immunotherapy company developing innovative treatments for patients with cancer, announced that it has completed the previously announced acquisition of XOMA Corporation's (NASDAQ:XOMA) antibody manufacturing ...
Form 8-K AGENUS INC For: Dec 31
Agenus Completes XOMA Antibody Manufacturing Pilot Plant Acquisition  Business Wire (press release)
Agenus Inc (NASDAQ:AGEN) Receives Average Rating of "Buy" from Analysts
Agenus logo Agenus Inc (NASDAQ:AGEN) has earned an average recommendation of “Buy” from the eight analysts that are covering the firm, Analyst Ratings Net reports.
Analysts Estimations: Agenus Inc  iStreetWire
Agenus Inc. Completes $115 Million Non-Dilutive Royalty Transaction with ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), an immunology company discovering and developing innovative treatments for cancers and other diseases, today announced a $115 million non-dilutive royalty transaction pursuant to ...
Agenus mortgages some vaccine royalties for $115M in R&D cash  FierceBiotech
Agenus Inks $115M Royalty Loan Tied to Two GSK Vaccines  Genetic Engineering & Biotechnology News
Stock under Consideration: Agenus Inc
The shares of Agenus Inc (NASDAQ:AGEN) currently has mean rating of 1.67 while 3 analysts have recommended the shares as “BUY”, 2 recommended as “OUTPERFORM” and 1 recommended as “HOLD”.
Brokerages Expect Agenus Inc (NASDAQ:AGEN) Will Post Earnings of -$0.18 Per Share
Agenus logo Analysts expect Agenus Inc (NASDAQ:AGEN) to report earnings per share (EPS) of ($0.18) for the current fiscal quarter, according to Zacks.
Detwiler Fenton Investment Management Purchases $78000 Shares of Agenus Inc ...  Corvus Business Newswire
Agenus Inc (AGEN) Sees Large Decline in Short Interest
Agenus logo Agenus Inc (NASDAQ:AGEN) was the target of a large drop in short interest during the month of December. As of December 31st, there was short interest totalling 9,231,755 shares, a drop of 21.3% from the December 15th total of 11,727,191 ...
Agenus Inc. Price Target Update  Analyst Rating Reports
Agenus Inc (AGEN) Upgraded to "Buy" by Zacks Investment Research
Agenus Inc logo Zacks Investment Research upgraded shares of Agenus Inc (NASDAQ:AGEN) from a hold rating to a buy rating in a research report sent to investors on Monday, MarketBeat Ratings reports.
William Blair Weighs in on Agenus Inc's FY2016 Earnings (AGEN)  IRA Market Report
Agenus Inc. Analyst Rating Update  Bull Report